home > ict > spring 2020 > turning over the right stones: rethinking the recruitment process
International Clinical Trials

Turning Over the Right Stones: Rethinking the Recruitment Process

From poorly designed protocols and insufficient staff to cumbersome technology and delays in study startup processes, clinical research sites face a constellation of challenges in getting a trial on its feet. Failing to launch on time leads to costly delays, or worse.

It takes, on average, more than 31 weeks from site identification to study start-up completion (1). Roughly 30-40% of sponsors and CROs report being somewhat or completely unsatisfied with their site initiation processes (2). Given these statistics, maybe it’s time to change the way the industry approaches study start-up, beginning with a careful review of recruitment and enrolment.

Expanding Your Reach by Narrowing Your Focus

Paid media campaigns for patient identification are wide-reaching, convenient to implement, and, in the right situation, integral to achieving enrolment. It’s not an overstatement to say this approach is the industry standard for identifying volunteers. However, failure to enrol enough subjects in a trial is a long-standing problem; one need only look at the literature over the past decade or two. It’s news to no one. So, what’s the problem?

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the author

Tyler Bye is a career clinical research professional with over 12 years’ experience with sites, sponsors, and vendors alike. As the Associate Director of Program Management at WCG ThreeWire, Tyler specialises in the development and implementation of clinical research site optimisation services across pharma, biotech, and medical device industries. Before joining WCG ThreeWire, Tyler was a sponsor representative who managed clinical trials. He also spent countless hours working with patients at a prominent clinical research site.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nouscom Announces Janssen Receives US FDA IND Clearance for VAC85135, an ‘Off-The-Shelf’ Cancer Immunotherapy Developed Using Nouscom’s Proprietary Viral Vector Platform

BASEL, Switzerland – 17th May 2022 - Nouscom, a clinical stage immuno-oncology company developing both off-the-shelf and personalized cancer neoantigen immunotherapies, today announced that Janssen Research & Development, LLC (Janssen) received U.S. Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) candidate VAC85135, an off-the-shelf, viral vector-based cancer vaccine for an oncologic indication. VAC85135 has been exclusively licensed to Janssen.
More info >>

White Papers

Speciality Logistics Outlook 2015

World Courier

To date, there are more than 178,000 registered clinical trials taking place across the globe, and global pharma’s volume has more than doubled over the last decade. With emerging markets showing explosive predictive growth through 2016, shippers and trial sponsors can expect continued regulatory and overall logistics complexities that foster demand for local, inmarket resources across the globe.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement